newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

  • IGC Pharma announced that its "AHA: Agentic Harmonization Assistant" project was selected as a semi-finalist in the $1 million Alzheimer's Insights AI Prize organized by the Alzheimer's Disease Data Initiative (ADDI).
  • CEO Ram Mukunda stated the recognition validates the company's proprietary MINT-AD deep-learning platform, which integrates clinical, neuroimaging, genetic, lifestyle, cognitive, and genomic data to address data harmonization bottlenecks.
  • Semi-finalist teams are scheduled to present on December 5, 2025, in San Diego, California, following the Clinical Trials on Alzheimer's Disease (CTAD) conference.
  • ADDI is a global coalition of academic, governmental, philanthropic, & industry organizations aimed at accelerating Alzheimer's research through data sharing & collaboration.
  • IGC Pharma is a clinical-stage biotechnology company leveraging AI for Alzheimer's & metabolic disorders, with lead asset IGC-AD1 in a Phase 2 trial (CALMA) & additional pipeline programs targeting amyloid plaques, tau proteins, & neurodegeneration.
  • The company has filed more than 30 patents, received 12 grants, & includes standard forward-looking statements regarding regulatory approval, economic conditions, & AI algorithm performance.